{"id":"W3204212303","doi":"10.1016/j.annonc.2021.08.622","title":"339TiP SOLTI-1502 ARIANNA: Targeting PAM50 HER2-enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative metastatic breast cancer","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Genentech; Oncolytics Biotech; Eisai; Daiichi-Sankyo; Astellas Pharma US; Roche; Seagen; Puma Biotechnology; Novartis; Les Laboratories Pierre Fabre; Eli Lilly and Company; AstraZeneca; Daiichi Sankyo Europe; Breast Cancer Research Foundation; Amgen; Pfizer","keywords":"Enzalutamide; Medicine; Androgen receptor; Internal medicine; Tamoxifen; Oncology; Breast cancer; Estrogen receptor; Cancer research; Prostate cancer; Population; Exemestane; Cancer; Endocrinology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005327368,0.0003836266,0.001241263,0.0002309671,0.00007649878,0.00001323448,0.0001591799,0.0001842984,0.0005787135],"category_scores_gemma":[0.0003615214,0.0003330688,0.0001366465,0.0009802923,0.0004341452,0.0002593524,0.000102917,0.0005931521,0.00002739798],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003595236,"about_ca_system_score_gemma":0.001461705,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001436594,"about_ca_topic_score_gemma":0.001279446,"domain_scores_codex":[0.997098,0.0004631667,0.0007047246,0.0006331119,0.0003773139,0.0007236354],"domain_scores_gemma":[0.997163,0.0005588062,0.0005281518,0.0003587883,0.001167949,0.00022328],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.03074952,0.004711082,0.04837799,0.0006102305,0.004240095,0.00353564,0.01289712,0.001041376,0.3209914,0.001512349,0.00386381,0.5674694],"study_design_scores_gemma":[0.02708694,0.007756658,0.7168998,0.001528036,0.0006996823,0.001738896,0.01243544,0.0001434864,0.1985917,0.003497619,0.0280809,0.0015409],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9581548,0.009678432,0.0006600001,0.02784825,0.0002809555,0.0008198929,0.0001914048,0.00008247799,0.002283806],"genre_scores_gemma":[0.985467,0.002289519,0.008336254,0.002983287,0.0002640854,0.0001582789,0.00007653583,0.00008102977,0.0003440017],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6685218,"threshold_uncertainty_score":0.9999121,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03930127710637511,"score_gpt":0.3517432248888993,"score_spread":0.3124419477825242,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}